Pluristem Announces First Clinical Indication for PLX-RAD Cells for Use in Hematology
Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced today that it has identified its first clinical indication in the hematology field for its Placental eXpanded (PLX) RAD cells for the enhancement of the engraftment of Hematopoietic Stem Cells (HSC) in patients experiencing a delay or failure of their bone marrow transplant (BMT). This follows Pluristem's completion of additional pre-clinical studies showing promising results for PLX-RAD for this indication.
According to the National Marrow Donor Program, an estimated 25,000 allogeneic bone marrow transplants are performed annually worldwide. Approximately 15% of these patients will either have a delay or failure to engraft the HSCs, resulting in a condition that is life threatening, expensive and often requires the continued support of the patient with blood products. PLX-RAD may be beneficial to these patients.
PLX-RAD is currently being evaluated by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, in models of the acute radiation syndrome (ARS).
PLX-RAD, Pluristem's second product candidate, joins PLX-PAD that is in clinical trials for the treatment of peripheral artery disease, muscle injury and Pulmonary Hypertension. Both product